Epigenetic regulation in pulmonary heart disease by non-coding RNA
10.3969/j.issn.1001-1978.2021.03.005
- Author:
Guan-Lie LI
1
;
Ao SHEN
1
;
Xi-Yong YU
1
Author Information
1. Guangdong Key Lab of Molecular Target and Clinical Pharmacology, School of Pharmaceutical Sciences of Guangzhou Medical University, State Key Lab of Respiratory Diseases Pharmacology Group
- Publication Type:Journal Article
- Keywords:
epige- netics;
heart failure;
non-coding RNA;
pulmonary heart disease;
pulmonary hypertension;
right-heart remodeling
- From:
Chinese Pharmacological Bulletin
2021;37(3):317-322
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary heart disease (PHD) is a common cardiovascular disease in China, with high mortality ratein its late stage.Currently, PHD treatments are mainly to delay the disease progression, which cannot effectively improve and cure the disease.Consequently, it is in urgent need to find a new treatment for PHD.Epigenetic regulation plays an important role in the occurrence and pathological process of diseases, which provides a novel idea of developing new drugs by regulating non-coding RNA(ncRNA).However, ncRNA studies in PHD are at the stage of few and shallow, stray and scattered.Therefore, this review for the first time summarizes ncRNA related to various PHD phenotypes, and discusses the epigenetic regulation in PHD by ncRNA.
